Ketamine Versus Dexmedetomidine With Local Anesthetic in TAP Block
Comparison of the Analgesic Effect of Ketamine Versus Dexmedetomidine Added to Local Anesthetic in TAP Block for Lower Abdominal Cancer Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Assiut University
-
Assiut, Assiut University, Egypt, 171516
- South Egypt Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients ASA I and II to whom abdominal surgery for cancer will be conducted will be included in the study
Exclusion Criteria:
- Coagulopathies
- ASA III or IV, patient refusal, sensitivity to the used drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: control group,
saline in the same volume will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
|
Ketamine at a dose of 0.5mg/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
dexmedetomidine at a dose of 1ug/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
|
|
Active Comparator: ketamine group,
ketamine in a dose of 0.5mg/kg will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
|
dexmedetomidine at a dose of 1ug/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
20ml of 0.25% bupivacaine will be injected in each side of the TAP block
|
|
Active Comparator: dexmedetomidine group
dexmedetomidine in a dose of 1ug/kg will be added to the local anesthetic for TAP block in patients undergoing abdominal cancer surgery
|
Ketamine at a dose of 0.5mg/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
20ml of 0.25% bupivacaine will be injected in each side of the TAP block
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
postoperative rescue morphine consumption
Time Frame: 24 hours postoperative
|
postoperative rescue morphine consumption
|
24 hours postoperative
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Site
- Abdominal Neoplasms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Ketamine
- Dexmedetomidine
Other Study ID Numbers
Other Study ID Numbers
- 321
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postoperative Analgesia
-
NCT07191938Not yet recruitingPostoperative Care | Postoperative Analgesia | Analgesia Assessment | Posthectomy
-
NCT07258277Not yet recruiting
-
NCT06681493CompletedPostoperative Analgesia
-
NCT04720287Completed
-
NCT04690894Completed
-
NCT04689633CompletedPostoperative Analgesia
-
NCT03344393Unknown
-
NCT03258255CompletedPostoperative Analgesia
-
NCT03239314CompletedPostoperative Analgesia
Clinical Trials on Ketamine
-
NCT07401914Active, not recruitingGastrointestinal Endoscopy | Procedural Sedation
-
NCT07536633Completed
-
NCT07247006Not yet recruitingChronic Pain | Treatment Resistant Depression (TRD)
-
NCT07450430Not yet recruitingSickle Cell Disease | Sickle Cell Crisis
-
NCT05907213CompletedPain, Postoperative | Depression, Postpartum
-
NCT07429916RecruitingPain Management | Laparascopic Sleeve Gastrectomy
-
NCT07250867Not yet recruiting